Biomedicines, Vol. 12, Pages 928: Irisin and Its Role in Postmenopausal Osteoporosis and Sarcopenia

Biomedicines, Vol. 12, Pages 928: Irisin and Its Role in Postmenopausal Osteoporosis and Sarcopenia

Biomedicines doi: 10.3390/biomedicines12040928

Authors: Irene Falsetti Gaia Palmini Simone Donati Cinzia Aurilia Teresa Iantomasi Maria Luisa Brandi

Menopause, an extremely delicate phase in a woman’s life, is characterized by a drop in estrogen levels. This decrease has been associated with the onset of several diseases, including postmenopausal osteoporosis and sarcopenia, which often coexist in the same person, leading to an increased risk of fractures, morbidity, and mortality. To date, there are no approved pharmacological treatments for sarcopenia, while not all of those approved for postmenopausal osteoporosis are beneficial to muscles. In recent years, research has focused on the field of myokines, cytokines, or peptides secreted by skeletal muscle fibers following exercise. Among these, irisin has attracted great interest as it possesses myogenic properties but at the same time exerts anabolic effects on bone and could therefore represent the link between muscle and bone. Therefore, irisin could represent a new therapeutic strategy for the treatment of osteoporosis and also serve as a new biomarker of sarcopenia, thus facilitating diagnosis and pharmacological intervention. The purpose of this review is to provide an updated summary of what we know about the role of irisin in postmenopausal osteoporosis and sarcopenia.